"Our lead candidate GC012F, the BCMA/CD19 dual-targeting FasTCAR-T therapy, has demonstrated encouraging efficacy and differentiated safety profile in the 48 patients treated across three indications in three studies. This gives us a high level of conviction in the significant therapeutic potential of GC012F in a wide range of hematology and immunology indications. We recently received IND clearances from both the US FDA and China NMPA, and are on track to commence enrollment in these two Company-sponsored trials in RRMM in the coming months," said Dr. William Cao, founder, Chairman and CEO of Gracell. "Moreover, we plan to provide an important clinical data update on the response durability of GC012F in RRMM in mid-year 2023. Concurrently, we are expanding Gracell’s clinical pipeline across our technology platforms, including initiating a China IIT for SMART CAR-T GC506 in Claudin18.2-positive solid tumors in first half of 2023."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GRCL:
- Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update
- Gracell management to meet virtually with Jefferies
- Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
- Gracell: China’s NMPA clears IND application for GC012F
- Gracell: FDA clears IND application for Phase 1b/2 FasTCAR-T GC012F trial